XVA143

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 208223

CAS#: 264275-77-6

Description: XVA143 is a α/β I allosteric inhibitor of the integrin leucocyte function-associated antigen-1 (αLβ2, LFA-1) which plays crucial roles in T cell adhesion, migration and immunological synapse (IS) formation. Consequently, αLβ2 is an important therapeutic target in autoimmunity.

Chemical Structure

img
XVA143
CAS# 264275-77-6
Instruction

Theoretical Analysis

MedKoo Cat#: 208223
Name: XVA143
CAS#: 264275-77-6
Chemical Formula: C25H21Cl2N3O8
Exact Mass: 561.07
Molecular Weight: 562.340
Elemental Analysis: C, 53.40; H, 3.76; Cl, 12.61; N, 7.47; O, 22.76

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: XVA-143, XV-A143, XVA1-43

IUPAC/Chemical Name: (2S)-2-[[2,6-Dichloro-4-[(3-hydroxyphenyl)methylcarbamoyl]benzoyl]amino]-3-[(3,5-dihydroxybenzoyl)amino]propanoic acid

InChi Key: FZKFBGXSXUYBMX-FQEVSTJZSA-N

InChi Code: InChI=1S/C25H21Cl2N3O8/c26-18-7-14(23(35)28-10-12-2-1-3-15(31)4-12)8-19(27)21(18)24(36)30-20(25(37)38)11-29-22(34)13-5-16(32)9-17(33)6-13/h1-9,20,31-33H,10-11H2,(H,28,35)(H,29,34)(H,30,36)(H,37,38)/t20-/m0/s1

SMILES Code: OC1=CC(C(NC[C@H](NC(C2=C(Cl)C=C(C(NCC3=CC(O)=CC=C3)=O)C=C2Cl)=O)C(O)=O)=O)=CC(O)=C1

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: To be determined

Shelf Life: >2 years if stored properly

Drug Formulation: To be determined

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 562.34 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Mancuso RV, Welzenbach K, Steinberger P, Krähenbühl S, Weitz-Schmidt G. Downstream effect profiles discern different mechanisms of integrin αLβ2 inhibition. Biochem Pharmacol. 2016 Nov 1;119:42-55. doi: 10.1016/j.bcp.2016.09.002. Epub 2016 Sep 6. PMID: 27613223.

2: Hajishengallis G, Shakhatreh MA, Wang M, Liang S. Complement receptor 3 blockade promotes IL-12-mediated clearance of Porphyromonas gingivalis and negates its virulence in vivo. J Immunol. 2007 Aug 15;179(4):2359-67. doi: 10.4049/jimmunol.179.4.2359. PMID: 17675497.

3: Salas A, Shimaoka M, Kogan AN, Harwood C, von Andrian UH, Springer TA. Rolling adhesion through an extended conformation of integrin alphaLbeta2 and relation to alpha I and beta I-like domain interaction. Immunity. 2004 Apr;20(4):393-406. doi: 10.1016/s1074-7613(04)00082-2. PMID: 15084269.

4: D'Elia R, Jenner DC, Laws TR, Stokes MG, Jackson MC, Essex-Lopresti AE, Atkins HS. Inhibition of Francisella tularensis LVS infection of macrophages results in a reduced inflammatory response: evaluation of a therapeutic strategy for intracellular bacteria. FEMS Immunol Med Microbiol. 2011 Aug;62(3):348-61. doi: 10.1111/j.1574-695X.2011.00817.x. Epub 2011 Jun 16. PMID: 21569124.

5: Parmley LA, Elkins ND, Fini MA, Liu YE, Repine JE, Wright RM. Alpha-4/beta-1 and alpha-L/beta-2 integrins mediate cytokine induced lung leukocyte-epithelial adhesion and injury. Br J Pharmacol. 2007 Nov;152(6):915-29. doi: 10.1038/sj.bjp.0707443. Epub 2007 Sep 10. PMID: 17828290; PMCID: PMC2078224.

6: Wilson ZS, Ahn LB, Serratelli WS, Belley MD, Lomas-Neira J, Sen M, Lefort CT. Activated β2 Integrins Restrict Neutrophil Recruitment during Murine Acute Pseudomonal Pneumonia. Am J Respir Cell Mol Biol. 2017 May;56(5):620-627. doi: 10.1165/rcmb.2016-0215OC. PMID: 28157452; PMCID: PMC5449489.

7: Hajishengallis G, McIntosh ML, Nishiyama SI, Yoshimura F. Mechanism and implications of CXCR4-mediated integrin activation by Porphyromonas gingivalis. Mol Oral Microbiol. 2013 Aug;28(4):239-49. doi: 10.1111/omi.12021. Epub 2013 Jan 21. PMID: 23331495; PMCID: PMC4123224.

8: Xiang X, Lee CY, Li T, Chen W, Lou J, Zhu C. Structural basis and kinetics of force-induced conformational changes of an αA domain-containing integrin. PLoS One. 2011;6(11):e27946. doi: 10.1371/journal.pone.0027946. Epub 2011 Nov 28. PMID: 22140490; PMCID: PMC3225382.

9: Chen W, Lou J, Zhu C. Forcing switch from short- to intermediate- and long- lived states of the alphaA domain generates LFA-1/ICAM-1 catch bonds. J Biol Chem. 2010 Nov 12;285(46):35967-78. doi: 10.1074/jbc.M110.155770. Epub 2010 Sep 6. Erratum in: J Biol Chem. 2011 May 20;286(20):18344. PMID: 20819952; PMCID: PMC2975219.

10: Tardif MR, Gilbert C, Thibault S, Fortin JF, Tremblay MJ. LFA-1 antagonists as agents limiting human immunodeficiency virus type 1 infection and transmission and potentiating the effect of the fusion inhibitor T-20. Antimicrob Agents Chemother. 2009 Nov;53(11):4656-66. doi: 10.1128/AAC.00117-09. Epub 2009 Aug 31. PMID: 19721069; PMCID: PMC2772324.